Fibromyalgia

"Fibromyalgia is best managed as a chronic condition, with non-pharmacological therapies as the primary treatment and medications as an adjunct to symptom relief.”

Enrollment in the FIT Teens program, which began in January 2018, was paused in March 2020 to revise operations manuals, conduct remote treatment sessions to evaluate accuracy and fidelity, obtain regulatory approvals, and train staff on the new procedures.

Fibromyalgia commonly presents as widespread pain, physical, and cognitive symptoms. Unfortunately, it often manifests differently among patients and can be difficult to diagnose and treat.

Take a few minutes to catch up on the latest rheumatology news for the month of November 2022.

As cannabis use continues to rise worldwide, investigators question its role in treating fibromyalgia, a common pain syndrome that affects women twice as much as men.

Personalizing non-pharmacological treatment for patients with fibromyalgia using a targeted symptom approach may improve outcomes.

EULAR guidelines suggest that non-pharmacological therapies should be prioritized over treatment with medication.

The association between type of body composition and fibromyalgia was evaluated using 43 women with clinically diagnosed fibromyalgia.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 5, 2022.

Investigators note that healthcare approaches may benefit from including patient-reported experiences of living with and being treated for fibromyalgia.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 22, 2022.

“Exercise is an important component of the treatment of fibromyalgia, but there was not a consensus understanding of the effect of various exercise programs on the quality of life, pain, and physical function of people with fibromyalgia.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 8, 2022.

Results underline the importance of psychiatric evaluation and treatment in patients with fibromyalgia.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2022.

The 3-stage Delphi exercise used the expertise of medical and health care professionals with experience in treating patients with fibromyalgia. Treatment recommendations included exercise, education, cognitive behavioral therapy, mindfulness, and mind-body exercises.

Rheumatology Network's month in review spotlights the most popular content from the past month.

Fibromyalgia patients have 3 times the rate of depression compared with those without the condition and more than 50% of patients with fibromyalgia experience lifetime depression.

Despite previous evidence showing the benefits of vitamin D supplementation in patients with fibromyalgia and chronic widespread musculoskeletal pain, controversy still exists over the role of 25OHD in the treatment of these diseases.

C-reactive protein (CRP), an acute phase protein produced mainly by liver hepatocytes in response to interleukin-6 (IL-6), is a non-specific marker of inflammation.

Data indicate that higher levels of perceived pain related disability and greater difficulty falling asleep was associated with increased anxiety levels in adults with fibromyalgia and insomnia.

Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

“Considering the fact that people with one and the same clinical condition can vary substantially in terms of disability, there is a need to expand the assessment tools,” investigators stated.

Clinical features of fibromyalgia are more common in participants who had postacute COVID-19 syndrome.